摘要
目的评价恩替卡韦联合安络化纤丸治疗乙型肝炎肝硬化的疗效。方法纳入恩替卡韦联合安络化纤丸治疗乙型肝炎肝硬化的随机对照试验(RCT)研究结果,对照组均为恩替卡韦。采用Rev Man 5.1软件进行Meta分析。结果恩替卡韦联合安络化纤丸治疗乙型肝炎肝硬化能使患者肝功能ALT和TBLL水平均有不同程度改善,肝硬化指标:HA、LN、PCIII、IV-C优于对照组,差异有显著性。观测指标纳入文献都小于7篇,故而无法进行漏斗图分析。结论恩替卡韦联合安络化纤丸治疗乙型肝炎肝硬化,较单用恩替卡韦治疗能更好抗肝硬化,具有更大的潜力。
Objective To evaluate the effect of entecavir（ ETV） combined with Anluohuaxian pills in the treatment of hepatitis B-related cirrhosis. Methods The RCT studies of combination therapy of entecavir（ ETV） and Anluohuaxian for cirrhosis patients with hepatitis B were searched,while the control group received ETV. So as to Rev Man 5. 1 software was used for Meta analysis. Results Entecavir in combination with Anluohuaxian pills could improve the level of ALT and TBLL,the integrative therapy could also significantly reduce the liver fibrosis indexes： HA,LN,PCIII,IV-C which were better than those of the control group,and there were significant differences. The observation of literatures were less than 7 papers,so we cannot make the funnel plot analysis. Conclusion ETV in combination with Anluohuaxian pills have better than single use of ETV on the patients with hepatitis B-related cirrhosis,and has a greater potential.
出处
《光明中医》
2016年第12期1722-1726,共5页
GUANGMING JOURNAL OF CHINESE MEDICINE
